| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Medicine and
Immunology Program, Memorial Sloan-Kettering Cancer Center, New York City, NY 10021
One of several effector mechanisms thought to contribute to Ab efficacy against cancer is complement-dependent cytotoxicity (CDC). Serological analysis of a series of clinical trials conducted over a 10-year period suggested that six vaccines containing different glycolipids induced Abs mediating CDC whereas four vaccines containing carbohydrate or peptide epitopes carried almost exclusively by mucin molecules induced Abs that did not mediate CDC. To explore this further, we have now compared cell surface reactivity using flow cytometry assays (FACS), complement-fixing ability, and CDC activity of a panel of mAbs and immune sera from these trials on the same two tumor cell lines. Abs against glycolipids GM2, globo H and Lewis Y, protein KSA (epithelial cell adhesion molecule, also known as EpCAM) and mucin Ags Tn, sialylated Tn, Thomsen Friedenreich (TF), and MUC1 all reacted comparably by FACS with tumor cells expressing these Ags. Compared with the strong complement binding and CDC with Abs against glycolipids and KSA, complement binding was diminished with Abs against mucin Ags and no CDC was detected. A major difference between these two groups of Ags is proximity to the cell membrane. Glycolipids and globular glycoproteins extend less than 100 Å from the cell membrane while mucins extend up to 5000 Å. Although complement activation at sites remote from the cell membrane has long been known as a mechanism for resistance from complement lysis in bacteria, it is identified here for the first time as a factor which may contribute to resistance from CDC against cancer cells.
This article has been cited by other articles:
|
|
 |
|
  S. Wilkie, G. Picco, J. Foster, D. M. Davies, S. Julien, L. Cooper, S. Arif, S. J. Mather, J. Taylor-Papadimitriou, J. M. Burchell, et al. Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor J. Immunol., April 1, 2008; 180(7): 4901 - 4909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Sabbatini, G. Ragupathi, C. Hood, C. A. Aghajanian, M. Juretzka, A. Iasonos, M. L. Hensley, M. K. Spassova, O. Ouerfelli, D. R. Spriggs, et al. Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4170 - 4177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Gilewski, G. Ragupathi, M. Dickler, S. Powell, S. Bhuta, K. Panageas, R. R. Koganty, J. Chin-Eng, C. Hudis, L. Norton, et al. Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21 Clin. Cancer Res., May 15, 2007; 13(10): 2977 - 2985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Luo, E. Ko, J. C.-f. Hsu, X. Wang, and S. Ferrone Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects J. Immunol., May 15, 2006; 176(10): 6046 - 6054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yin, A. Hashimoto, M. Izawa, K. Miyazaki, G.-Y. Chen, H. Takematsu, Y. Kozutsumi, A. Suzuki, K. Furuhata, F.-L. Cheng, et al. Hypoxic culture induces expression of sialin, a sialic Acid transporter, and cancer-associated gangliosides containing non-human sialic Acid on human cancer cells. Cancer Res., March 15, 2006; 66(6): 2937 - 2945. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
